1 mL BAC
20 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 1 mL
Shown in the diagram. Closest of these examples to 25 units.
SingleInvestigationalPhase 3Moderate confidenceSourced
Retatrutide
A triple GIP, GLP-1 and glucagon receptor agonist in phase 3 development. Explore the TRIUMPH schedule and vial-aware calculation examples.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
TRIUMPH phase 3 design
Weekly research schedule
The default line reconstructs the 12 mg TRIUMPH phase 3 arm, starting at 2 mg and changing every four weeks through 4 mg, 6 mg and 9 mg.
Maximum study quantityChoose the maximum shown by the evidence line. Any earlier point can be selected below for its arithmetic.
Assigned weekly quantities
Select a point for its calculation examples- Weeks 1 to 42 mg
- Weeks 5 to 84 mg+2 mg after 4 weeks
- Weeks 9 to 126 mg+2 mg after 4 weeks
- Weeks 13 to 169 mg+3 mg after 4 weeks
- Weeks 17 to 8012 mg+3 mg after 4 weeks
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 2 mg study quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
1 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw20 U
20-30 U reference band
2 mL BAC
40 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 2 mL
3 mL BAC
60 units
resulting U-100 draw
- Concentration
- 3.333 mg/mL
- BAC added
- 3 mL
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudySubcutaneousOnce weekly
Adults with obesity or overweight without diabetes
Once-weekly phase 3 trial arms targeting 4 mg, 9 mg or 12 mg after a 2 mg start and four-week escalation steps
TRIUMPH-1 used the sequence 2 mg, 4 mg, 6 mg, 9 mg and 12 mg for the highest target arm. These were assigned research schedules, not prescribing instructions.
View sourceHuman StudySubcutaneousOnce weekly
Adults with obesity or overweight without diabetes
Once-weekly subcutaneous trial arms targeting 1 mg, 4 mg, 8 mg or 12 mg, with lower starting-dose groups and dose escalation
Phase 2 randomised controlled study over 48 weeks; these were research arms rather than prescribing instructions.
View sourceCommunity GuideSubcutaneous in reportsUsually once weekly; nonweekly schedules are experimental
online research community reports
Weekly use dominates, commonly beginning around 2 mg and clustering at 8-12 mg weekly during reported loss phases; maintenance reports span 0.5 mg weekly to 9-10 mg weekly
Split, every-three-to-five-day and daily schedules are fringe experiments, not trial conversions. The archive also contains a corrected 10 mg-every-five-days example that a refined file mistranscribed as 2 mg; raw/stacking-glp1s-a-contrarian-view.md:399 and dosing-summaries/01-retatrutide.md:18-53.
View sourceCommunity GuideSubcutaneous in reportsUsually once weekly; every 5-6 days is a common variant
authenticated research-forum (Peppys) weight-loss reports
Subcutaneous weekly use dominates, commonly beginning around 2 mg and titrating stepwise (for example 2-4-6-8-9-10-12 mg, roughly four weeks per step) toward 8-12 mg, with 12 mg the reported maximum and effects said to "feel" around 6-8 mg; some run every 5-6 days tracking the ~6-day half-life, and low-dose responders report 1-2 mg weekly
Forum provenance from an authenticated archive with usernames omitted. Split, every-three-to-five-day and daily schedules are described as fringe experiments rather than trial conversions; the archive notes effects build over about eight weeks with weight loss starting near week twelve. Quantities conflict and are community provenance, not controlled dose finding.
View sourceEvidence summary
Retatrutide activates three metabolic hormone receptors and remains an investigational medicine. Phase 3 topline results are available from the sponsor, while peer-reviewed phase 2 data remain important context.
How to read the studied regimen
The default line describes the assigned 12 mg target arm in TRIUMPH-1. Participants started at 2 mg and moved through 4 mg, 6 mg and 9 mg at four-week intervals before reaching 12 mg. Select a point to see the corresponding arithmetic, not to choose a personal quantity.
What the vial examples mean
The examples hold BAC water at 1 mL, 2 mL or 3 mL and show the resulting U-100 draw for the selected study quantity. No basic example exceeds a 3 mL vial. They do not verify solubility, headspace, sterility, stability or whether the labelled vial quantity is accurate.
Safety context
The phase 3 sponsor report and phase 2 paper should be read with their study populations, adverse events and discontinuations. Trial monitoring cannot be reproduced by a calculator.
Community provenance (Peppys)
A well-populated authenticated research-forum archive records subcutaneous retatrutide as a weekly compound, most often begun around 2 mg and titrated in roughly four-week steps toward 8-12 mg, with 12 mg described as the maximum and noticeable effects reported around 6-8 mg. A common variant doses every five to six days to track the roughly six-day half-life, while split, every-three-to-five-day and daily schedules are treated as fringe experiments. Low-dose responders and cagrilintide or tirzepatide stacking also appear. The same archive notes that effects build over about eight weeks with weight loss starting near week twelve, and records conflicting quantities. Usernames are omitted and figures are logged as community provenance without endorsement; these reports do not convert the trial schedule above.
Warnings and contraindications
Retatrutide is investigational and is not authorised for routine clinical use.
Gastrointestinal adverse events and heart-rate changes were reported in trials.
FDA states that retatrutide has not been found safe and effective for any condition and cannot be used in compounding under US federal law.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Bacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.